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Burkitt-like lymphoma with 11q aberration is characterized by patho-logical features and gene expression profile resembling those ofBurkitt lymphoma but lacks the MYC rearrangement and carries an
11q-arm aberration with proximal gains and telomeric losses. Whether this
lymphoma is a distinct category or a particular variant of other recognized
entities is controversial. To improve the understanding of Burkitt-like lym-
phoma with 11q aberration we performed an analysis of copy number
alterations and targeted sequencing of a large panel of B-cell lymphoma-
related genes in 11 cases. Most patients had localized nodal disease and a
favorable outcome after therapy. Histologically, they were high grade B-cell
lymphoma, not otherwise specified (8 cases), diffuse large B-cell lymphoma
(2 cases) and only one was considered as atypical Burkitt lymphoma. All
cases had a germinal center B-cell signature and phenotype with frequent
LMO2 expression. The patients with Burkitt-like lymphoma with 11q aber-
ration had frequent gains of 12q12-q21.1 and losses of 6q12.1-q21, and
lacked common Burkitt lymphoma or diffuse large B-cell lymphoma alter-
ations. Potential driver mutations were found in 27 genes, particularly
involving BTG2, DDX3X, ETS1, EP300, and GNA13. However, ID3, TCF3,
or CCND3 mutations were absent in all cases. These results suggest that
Burkitt-like lymphoma with 11q aberration is a germinal center-derived
lymphoma closer to high-grade B-cell lymphoma or diffuse large B-cell lym-
phoma than to Burkitt lymphoma.  
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ABSTRACT
Introduction
Our knowledge of lymphomas in children and young adults has increased dramat-
ically in the last years with the identification of several subtypes that predominantly
occur in this age subgroup.1-4 One of these recently recognized categories is Burkitt-
like lymphoma with 11q aberration (BLL-11q) which has morphological, phenotyp-
ic, and gene expression profiles resembling those of Burkitt
lymphoma (BL), but lacks MYC rearrangements according
to standard methods of detection, such as fluorescence in
situ hybridization (FISH). Alternatively, these tumors carry
an 11q-arm aberration characterized by proximal gains and
telomeric losses.4 In comparison with BL, BLL-11q seems
to have more complex karyotypes, a certain degree of
cytological pleomorphism, sporadically a follicular pattern
and a high incidence of nodal presentation.4,5 Very similar
cases have also been reported in the post-transplant set-
ting,6 although its incidence in other immunocompromised
conditions, such as human immunodeficiency infection, is
still unclear.7,8
BLL-11q has been incorporated in the revised World
Health Organization (WHO) classification as a provisional
category1 because its precise taxonomy as a particular vari-
ant of BL, diffuse large B-cell lymphoma (DLBCL) or a dis-
tinct form of high-grade B-cell lymphoma (HGBCL) is still
controversial.1,4-6,9-11 The clarification of the biological
nature of this uncommon subtype of lymphoma is clini-
cally relevant because of increasing interest in defining the
most appropriate management strategies for specific sub-
types of lymphomas in pediatric and young adult
patients.12 Recent DNA copy number alteration and next-
generation sequencing studies have provided a compre-
hensive catalog of genomic aberrations in BL and DLBCL
which clearly distinguish these entities.13-17 In this study
we performed an integrated analysis of genomic and
mutational alterations with a complete annotation of clin-
ical and pathological features of BLL-11q with the goal of
obtaining insights to refine the understanding of the
pathogenesis of these tumors and improve their diagnosis.  
Methods
Sample selection and DNA/RNA extraction
To identify BLL-11q cases we initially reevaluated the presence
of MYC translocations in 95 cases diagnosed as BL, atypical BL or
HGBCL, not otherwise specified (NOS), in our Hematopathology
Unit between 2000-2016. Three consultation cases from centers
belonging to the Sociedad Española de Hematología y Oncología
Pediátricas (SEHOP) were also analyzed. Cases were reviewed by
three pathologists (BG-F, EC, ESJ). DNA and RNA were extracted
using standard protocols (Qiagen, Hilden, Germany). This study
was approved by the Institutional Review Board of the Hospital
Clinic of Barcelona. Informed consent was obtained from all
patients in accordance with the Declaration of Helsinki.
Immunohistochemistry and fluorescence in situ
hybridization
Immunohistochemical analysis using a panel of antibod-
ies detecting common B- and T-cell markers as well as
LMO2 and MYC was performed and interpreted as previ-
ously reported (Online Supplementary Table S1).18,19
MYC breaks and MYC/IGH fusions were analyzed by
FISH using the XL MYC BA Probe (Metasystems,
Altlussheim, Germany) and LSI IGH/MYC/CEP 8 Tri-
Color Dual Fusion Probe Kit (Vysis-Abbott, Abbott Park,
IL, USA) respectively. The 11q alteration was studied with
a custom FISH probe using BAC clones (Invitrogen Inc.)
for proximal gains (RP11-414G21-spectrum green) and ter-
minal losses (RP11-629A20-spectrum red) combined with
CEP11-spectrum aqua (Vysis-Abbott Inc.). The FISH con-
stellation in a normal case is characterized by two signals
per probe, while the pattern corresponding to the 11q
gain/loss or gain/amplification/loss aberration would be
two blue, three up to five green signals and one red signal.
The probe was tested in an independent series of eight
non-Hodgkin B-cell lymphomas and four MYC-negative
HGBCL with lack of the 11q alteration by array analysis
and all showed the normal pattern described above.
Copy number analysis
DNA was hybridized on Oncoscan FFPE or SNP array platform
(ThermoFisher Scientific, Waltham, MA, USA) and analyzed as
described previously (Online Supplementary Methods).2 Published
copy number data on MYC-positive BL20 and DLBCL13 were rean-
alyzed for comparison.
Sequencing approaches
The mutational status of 96 B-cell lymphoma-related genes
(Online Supplementary Table S2) was examined by target next-gen-
eration sequencing in ten BLL-11q cases and four MYC-negative
11q-negative cases using a NGS SureSelect XT Target Enrichment
System Capture strategy (Agilent Technologies, Santa Clara, CA,
USA) before sequencing in a MiSeq instrument (Illumina, San
Diego, CA, USA) (Online Supplementary Methods). Additionally,
analysis of hotspots of mutation in ID3, TCF3 and CCND3 genes,
ETS1 exon 1 (transcript NM_005238) and verification of variants
in specific cases was performed by Sanger sequencing using
primers described in Online Supplementary Table S3.
Gene expression analysis
Cell of origin was determined by Lymph2Cx assay (Nanostring,
Seattle, WA, USA) as previously published.21 Gene expression lev-
els of MYC and ETS1 were investigated by real-time quantitative
polymerase chain reaction (Online Supplementary Methods) using
Taqman assays described in Online Supplementary Table S4.
Statistical methods
The χ2 method was used for categorical variables and Student t-
tests for continuous variables. Non-parametric tests were applied
when necessary. The P-values for multiple comparisons were
adjusted using the Benjamini–Hochberg correction. Survival
curves were estimated with the Kaplan-Meier method. Statistical
analyses were carried out with SPSS v22 and R software v3.1.3.
Results 
Identification of cases with Burkitt-like lymphoma with
11q aberration
To identify BLL-11q cases we reevaluated the presence of
MYC translocations in 95 cases diagnosed as having BL,
atypical BL or HGBCL, NOS. We confirmed the presence of
MYC rearrangements in 78 cases (82.1%), of which 67
(70.5%) were classified as BL. Since the 11q aberration has
been found mainly in children and young adults (<40 years
old),4 we analyzed the 60 patients under 40 years and the 35
older patients separately (Online Supplementary Figure S1).
In the younger cohort (n=60), the 46 (76.7%) cases with
MYC translocations were classified as having BL. To find
BLL-11q cases, we initially used the Oncoscan platform in
the remaining 14 MYC-negative patients and detected the
presence of the 11q gain/loss alteration in eight of them.
Additionally, we found a copy number pattern consistent
with the presence of 11q alteration in three recent consul-
tation cases from SEHOP (Online Supplementary Figures S1
and S2). Then, among those BLL-11q cases we were able
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to verify the presence of the 11q aberration by FISH in all
ten evaluable cases (Online Supplementary Figure S3 and
Supplementary Table S5). The morphological, clinical, and
genetic features and consensus diagnosis of the 11 BLL-
11q identified in our files are summarized in Table 1. The
six cases negative for the MYC rearrangement and 11q
aberrations by Oncoscan were re-classified as DLBCL (3
cases) or HGBCL, NOS (3 cases). The DLBCL had pre-
dominant centroblastic morphology, germinal center phe-
notype, very high proliferative index and a focal “starry
sky” pattern (see Online Supplementary Results). The
absence of 11q alterations was also verified using the 11q
FISH probe in four of these MYC/11q-negative cases with
available material (Online Supplementary Figure S1A). 
In the 35 older patients (≥40 years old), a MYC translo-
cation was found in 32 cases; one was classified as
DLBCL, 21 as BL, and ten were HGBCL with double- or
triple-hit aberrations (BCL2 and/or BCL6 translocations).
Only three cases were negative for MYC translocations
and were classified as HGBCL, NOS (Online Supplementary
Figure S1B and Online Supplementary Results). We screened
these cases with the 11q FISH probe and all three were
negative for the 11q aberration.
Clinical and morphological results of cases 
of Burkitt-like lymphoma with 11q aberration
The 11 patients with BLL-11q had a mean age of 15
years (range, 8-37 years); eight were male (Table 1). Eight
tumors were reclassified morphologically as HGBCL,
NOS, two as DLBCL and only one case was considered
atypical BL. None of the cases was considered as typical
BL (Figure 1). Six cases showed a “starry sky” pattern and
two had a nodular growth pattern with the presence of a
disrupted follicular dendritic cell meshwork (Figure 1C).
Ki67 was very high in all the samples, as in BL. All cases
had a germinal center (GC) phenotype and GC B-cell
(GCB) signature by Nanostring Lymph2Cx assay.
MUM1/IRF4 was negative in all 11 cases. One case
expressed BCL2 (Figure 1D). LMO2, a germinal center
marker that is usually seen in GCB-DLBCL but not in BL18
was expressed in five cases (Figure 1A, B). Interestingly,
using a 40% cutoff,19 five cases were positive for MYC
expression. However, only one case showed diffuse and
intense positivity while the other four cases had either
only positivity in around 50% of the cells or the intensity
was not that expected in typical BL. Additionally, MYC
RNA levels were significantly lower in BLL-11q than in
MYC-positive BL (relative expression 0.07 vs. 0.36,
P=0.019) (Online Supplementary Figure S4A). Epstein-Barr
virus hybridization was negative in the nine cases tested.
Clinically, BLL-11q frequently had a nodal localized
presentation (8/11) in the head and neck region. Two
cases had an extranodal presentation, one in the context
of an acute appendicitis and the other debuted as an
omental mass. Eight patients (73%) had stage I-II, and
one patient presented in an advanced stage (IV-E) with
Table 1. Pathological and clinical features of 11 cases of Burkitt-like lymphoma with 11q aberration.
Case     Age/            Biopsy             Original           Final                 Immunophenotype                     Stage*            COO         Chemo-   Rituximab   Outcome/
             gender             site               diagnosis      diagnosis                                                                                              Nanostring     therapy                       follow-up
                                                                                                    CD10&     IRF4/    BCL2  LMO2   MYC                      (Lymph2Cx)
                                                                                                      BCL6      MUM1
#1             27, M       Laterocervical         Atypical       HGBCL, NOS           +                 -              -             -              +                I                     GCB                  A                Yes            CR, 72m
                                             LN                         BL                       
#2**         37,M              Axillary                Atypical            DLBCL                 +                 -              -            +              -              IV-E                  GCB                  A                Yes           CR, 112m
                                             LN                         BL
#3               8,F                 Tonsil                  HGBCL          DLBCL &               +                 -              -             -               -                II                    GCB                  P                 No            CR, 54m
                                                                                         HGBCL blastoid 
#4              17,F           Submaxilar             HGBCL       HGBCL, NOS           +                 -              -            +             +                I                     GCB                  A                Yes            CR, 22m
                                            LN
#5              14,F        Laterocervical          HGBCL        HGBCL with            +                 -             +           +              -                 I                     GCB                  P                 No            CR, 29m
                                             LN                                            features 
                                                                                            intermediate
                                                                                            between BL 
                                                                                              and DLBCL
#6             14,M            Appendix               HGBCL            DLBCL                 +                 -              -            +              -                II                    GCB                  P                 No            CR, 25m
#7              8, M        Laterocervical              BL             Atypical BL             +                 -              -             -               -                 I                     GCB                  P                 No           CR, 113m
                                             LN
#14            8,M         Laterocervical              BL        HGBCL  blastoid       +                 -              -             -        Weak +          II                    GCB                  P                 No            CR, 15m
                                             LN
#15           12,M        Laterocervical          DLBCL       HGBCL, NOS           +                 -              -             -              +                I                     GCB                  P                 No            CR, 35m
                                           mass
#16           14, M       Laterocervical          DLBCL       HGBCL, NOS           +                 -              -            +              -                III                    GCB                  P                Yes            CR, 12m
                                             LN                            
#17           16, M           Omentum              HGBCL       HGBCL, NOS           +                 -              -             -              +               III                    GCB                  A                Yes             CR, 4m
*Stage was established according to the St. Jude/International Pediatric NHL Staging System (IPNHLSS) or Ann Arbor staging system for pediatric and adult patients, respectively. COO: cell of
origin; M: male; F: female; LN: lymph node; BL: Burkitt lymphoma; HGBCL: high-grade B-cell lymphoma; NOS: not otherwise specified; DLBCL: diffuse large B-cell lymphoma; Epstein-Barr virus
in situ hybridization (EBER) was negative in all nine tested cases. E: extranodal; GCB: germinal center B-cell; A: adult schema protocol (R-CHOP or burkimab); P: pediatric schema protocol; CR:
complete response; m: months. All patients received central nervous system prophylaxis. **Human immunodeficiency virus (HIV)-positive patient 
B. Gonzalez-Farre et al.
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Figure 1. Morphological features of cases of Burkitt-like lymphoma with 11q aberration. (A1-A3) Case #2 shows the typical morphology of diffuse large B-cell lym-
phomas with large and irregular cells resembling centroblasts. This case was positive for (A2) LMO2 and negative for (A3) MYC. (B1-B3) Case #4 corresponds to a tumor
with high-grade B-cell lymphoma (HGBCL) morphology. It is composed mostly of medium-sized cells with mild heterogeneity. Note the “starry sky” pattern. This case was
positive for (B2) MYC and (B3) LMO2 expression. (C1-C2; case #7) Lymph node with nodular architecture and a “starry sky” pattern with large follicles and a disrupted







widespread disease in the context of chronic human
immunodeficiency virus infection. All cases were treated
with chemotherapy, including rituximab in five. All
patients were alive with no disease after a median follow-
up of 29 months (Table 1). 
Copy number analysis
The copy number analysis of all the 11 BLL-11q cases
showed a total of 78 alterations (mean 7.1; range, 2-15)
(Online Supplementary Tables S5 and S6). Seven cases had
the typical 11q gain/loss pattern (Figure 2A-B, Online
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Figure 2. Genetic features of cases of Burkitt-like lymphoma with 11q aberration. (A) Global copy number profile of the 11 cases of Burkitt-like lymphoma (BLL) with 11q
aberration. The horizontal axis indicates chromosomes from 1 to Y and p to q. The vertical axis indicates the frequency of the genomic aberration among the cases ana-
lyzed. Gains are depicted in blue, losses are depicted in red. (B) Individual copy number profile of case #16 showing a prototypical, gain, loss and amplification in the 11q
region. Each probe is aligned from chromosome 1 to Y and p to q arm. (C) Mutational overview of ten cases of BLL with 11q aberration. The heat map shows the case-
specific pattern of driver mutations found by next-generation sequencing. Each column represents a case and each row represents a gene. The right bar graph illustrates
the mutation frequency of each gene. (D) A diagram of the relative positions of driver mutations is shown for BTG2, ETS1 and GNA13 genes. Domains BTG2: BTG family
domain. Domains ETS1: PNT: pointed domain; TAD: transactivation domain; H-1/2: inhibitory a-helices 1/2; DBD: DNA binding domain; H4-5: a-helix 4/5. Domains GNA13:




Supplementary Figure S2), two cases had only an 11q termi-
nal deletion, one case showed a complex 11q alteration
with two gains and two losses, and finally one case had an
11q23.3-q25 copy number neutral loss of heterozygosity in
addition to gain (Online Supplementary Figure S2). Two min-
imal regions of gain were identified (chr11:103326831-
111737912/11q22.3-q23.1 and chr11:114767237-
116764582/11q23.3,hg19) whereas the minimal region of
loss was in chr11:128214400-132020453/11q24.3-q25
(including the ETS1 and FLI1 genes). No cases with
homozygous deletions of these two targets were observed
in our series. The breakpoint region between gain and loss
was not conserved and spanned from chr11:118352769 to
chr11:121062860. Amplifications in the 11q arm were
observed in four cases, with a minimal region
chr11:118347020-120155799/11q23.3, including the USP2
gene (Online Supplementary Figure S5). The most recurrent
copy number aberrations other than 11q were 12q12-q21.1
gains and 6q12.1-q21 losses (Figure 2A).
BLL-11q cases displayed similar levels of complexity as
MYC-positive BL (7.1 vs. 6 alterations/case),20 but signifi-
cantly lower than those of GCB-DLBCL (7.1 vs. 19, alter-
ations/case P<0.0001).13 The BLL-11q genomic profile dif-
fered from that of BL and DLBCL (Online Supplementary
Figure S6). BLL-11q had frequent gains of 5q21.3-q32 and
losses of 6q12.1-q21 and lacked the 1q gains seen in MYC-
positive BL. BLL-11q also lacked alterations typically seen
in GCB-DLBCL such as gains of 2p16.1 and 7p and losses
of 1p36.32. 
The six tumors negative for both MYC and 11q-aberra-
tions in patients younger than 40 years had similar levels of
genomic complexity as those observed in BLL-11q (11.8 vs.
7.1 alterations/case) (Online Supplementary Figure S7A). The
unique significant aberration that distinguished the two
groups was the presence/absence of the 11q aberration.
The review of the literature regarding other lymphoid
neoplasms confirmed that the 11q alteration observed in
BLL-11q is mainly absent in other lymphoma entities with
the exception of transformed follicular lymphoma (16%)
(Online Supplementary Results).22
Next-generation sequencing and gene expression
analysis 
Target next-generation sequencing showed a total of 49
potential driver mutations affecting 27 different genes
(mean=4.9 mutations per case) (Figure 2C, D, Online
Supplementary Figures S8 and S9; Online Supplementary
Table S7). Interestingly, all cases lacked the typical BL
mutations in ID3, TCF3, or CCND3 genes, and their muta-
tional profile was more similar to that of other GC-
derived lymphomas with recurrent mutations affecting
BTG2 (4 cases), DDX3X, ETS1, EP300, and GNA13 (3
cases each) (Online Supplementary Table S8). Five cases had
mutations in epigenetic modifier genes such as EP300,
CREBBP, KMT2C, EZH2, ARID1A, KMT2D, HIST1H1D
and HIST1H2BC. Two cases had concomitant TMEM30A
deleterious mutations associated with a 6q14.1 deletion as
seen in DLBCL but not in BL (Figure 2C).14-16
BTG2 mutations, found in four cases, comprised three
missense mutations and one deletion in a splicing site.
BTG2 is a tumor suppressor gene with an important role
in G1/S transition through inhibition of CCND1 in a pRb-
dependent mechanism.23 These BTG2-inactivating muta-
tions could release CCND1 inhibition and accelerate G1/S
transition. GNA13 mutations were found in three cases
including four missense and two nonsense mutations, and
one missense mutation in a splicing site. Two MYC mis-
sense mutations occurred in the central domain of the pro-
tein, but did not affect threonine phosphorylation sites
(Online Supplementary Table S7).24 ETS1 mutations have
been previously described in BLL-11q and activated B-cell
DLBCL13,17 but not in conventional BL (Online
Supplementary Table S8).14,15 We detected three coding
mutations located on the winged helix-turn-helix DNA-
binding domain but the previously described exon 1
mutations (NM_005238) were absent in this series. ETS1
RNA expression was lower in BLL-11q than in MYC-pos-
itive BL (relative expression 6.6 vs. 19.3, P<0.001) and was
also lower in ETS1-mutated than wild-type BLL-11q (rela-
tive expression 1.9 vs. 8.6, P=0.03) (Online Supplementary
Figure S4B). 
The mutational profile of four MYC-negative/11q alter-
ation-negative cases with material available was analyzed
using the same approach. No mutations in BTG2, EP300
or ETS1 genes were observed. Moreover, three out of four
did not harbor any BL-related mutation on ID3, TCF3 and
CCND3 whereas the fourth case had a mutational profile
commonly seen in BL with MYC, DDX3X, SMARC4,
CCND3 and TP53 mutations (Online Supplementary Figure
S7B).
Discussion
BLL-11q was initially recognized as a particular subset
of HGBCL that had an expression profile and some patho-
logical characteristics similar to those of BL but lacked
MYC-translocations and alternatively shared a common
pattern of gains at 11q23 associated with losses at 11q24-
qter. The particular features of these cases raise some
uncertainty on their precise categorization as a variant of
BL or a tumor related to other HGBCL.1,4-6,9-11 On the other
hand, the limited number of cases reported and the differ-
ent methodologies used for their recognition do not pro-
vide a clear view of their incidence and clinico-pathologi-
cal characteristics.    
In this study we searched our files for cases that could
be reclassified as BLL-11q among 95 tumors previously
classified as BL, atypical BL, or HGBCL, NOS and found
eight (8%) cases with the chromosomal aberration. These
cases, together with three additional cases received on
consultation, were investigated for copy number alter-
ations and mutational profiles and compared to the
genomic aberrations recently identified in BL, DLBCL, and
HGBCL.13-17 The complexity of BLL-11q was similar to that
of MYC-positive BL,20 but significantly lower than that of
GCB-DLBCL.13 The BLL-11q genomic profile differed
from that of BL and DLBCL (Online Supplementary Figure
S6). BLL-11q had frequent gains of 5q21.3-q32 and losses
of 6q12.1-q21 and lacked the 1q gains seen in MYC-posi-
tive BL. BLL-11q also lacked alterations typically seen in
GCB-DLBCL such as gains of 2p16.1 and 7p and losses of
1p36.32. Additionally, we identified a mutational profile
in BLL-11q which was different from that of MYC-posi-
tive BL since all cases lacked the typical BL mutations in
ID3, TCF3, or CCND3 genes and had mutations in BTG2,
DDX3X, and ETS1 not seen in BL. In addition, BLL-11q
had mutations in epigenetic modifier genes such as EP300,
CREBBP, KMT2C, EZH2, ARID1A, KMT2D, HIST1H1D
and HIST1H2BC, which are common in DLBCL, particu-
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larly of the GCB subtype. Other genes frequently mutated
in GCB-DLBCL but not in BL were GNA13 and
TMEM30A associated with 6q14.1.14-16
We also compared our results with those of two recent
studies on HGBCL (including double- and triple-hit lym-
phomas).25,26 These cases also have recurrent mutations in
histone modifier genes such as KMT2D, CREBBP and
EZH2 (Online Supplementary Table S8). Intriguingly,
HGBCL, NOS, mainly with MYC-translocations, shared
mutations in genes frequently mutated in both BL and
GC-DLBCL.25,26 All these observations suggest that BLL-
11q is a neoplasm closer to other GC-derived lymphomas
rather than BL in which the 11q aberration together with
other mutations may play a relevant role in their patho-
genesis. While this manuscript was under revision,
Wagener et al. published a mutational study of 15 BLL-11q
cases. Similar to our findings, no mutations in ID3/TCF3
were identified and those cases carried frequent mutations
in GC-DLBCL-associated genes such as GNA13, FOXO1
and EZH2. Intriguingly, that study did not find mutations
in BTG2, KMT2D, KMT2C or CREBBP observed in our
study.27 Collectively, these findings indicate that the
genomic and mutational profiles of BLL-11q are different
from those of BL and more similar to those of other GC-
derived lymphomas.
In addition to the genetic differences, our BLL-11q cases
differed clinically, morphologically and phenotypically
from conventional BL and instead showed features more
consistent with HGBCL or DLBCL. As in previous studies,
all our patients were younger than 40 years, although
occasional cases in older patients have been reported.4,5,27
Contrary to BL, most of our cases of BLL-11q presented
with localized lymphadenopathy.4,5,27 These cases have a
favorable outcome after therapy, although the optimal
clinical management remains to be determined.
Morphologically, our cases had a prominent “starry sky”
pattern and high proliferation rate (>90%) but did not
have the typical cytological features of BL since they were
better classified as HGBCL with blastoid or intermediate
features between HGBCL (8 cases) and DLBCL (2 cases)
and only one had features of atypical BL. As previously
reported,4 two of our cases displayed a follicular growth
pattern, with an underlying meshwork of follicular den-
dritic cells, raising the differential diagnosis with other
pediatric lymphomas such as large B-cell lymphoma with
IRF4 rearrangement.3 However, BLL-11q did not express
IRF4/MUM1 and often exhibited a “starry sky” pattern
with frequent mitotic figures, features that are not usual in
large B-cell lymphoma with IRF4 rearrangement. We also
identified different immunohistochemical stains that
could help in the differential diagnosis from other lym-
phomas entities. LMO2, a GC marker that is typically
downregulated in BL and other lymphomas with MYC
translocation,18 was detected in 46% of our BLL-11q cases.
In addition, and contrary to BL, MYC expression with a
diffuse and intense pattern was only detected in one of
our cases while the other four positive cases either exhib-
ited partial positivity or the intensity was weak contrary
to the pattern seen in BL. 
Negativity for MYC rearrangement is a crucial element
for the recognition of these cases. The recommended
technique for detecting MYC translocations in clinical
practice is FISH analysis using break-apart probes, with
the limitation that a subset of 4% of MYC-positive cases
are not detected with this method but picked up using
MYC/IGH probes.28 The genetic feature that distinguishes
BLL-11q is an alteration of the 11q arm that prototypically
is characterized by an 11q23.2-q23.3 gain/amplification
and 11q24.1-qter loss. Additionally, isolated cases have
been recognized with single 11q24.1-qter terminal loss or
11q23 gain with 11q24-qter copy number neutral loss of
heterozygosity.4,11 In our study we identified the presence
of these 11q alterations using copy number arrays. We
also confirmed the presence of 11q alterations by FISH
analysis with a custom probe in all tested cases, suggesting
that this approach may be useful in clinical practice to
identify such cases (Online Supplementary Table S8). The
specificity of this FISH approach was also confirmed by
the fact that no false positive cases were observed in the
12 lymphoma cases in which the array showed a normal
11q pattern. Nevertheless, more studies on the clinical
value of this probe are needed and, for the time being,
confirmation of the finding by copy number array would
be desirable. The specific 11q alteration observed in BLL-
11q should be distinguished from other 11q aberrations
such as 11q gains of the 11q24 region that include ETS1
and FLI1, detected in DLBCL,29 or the 11q25 losses missing
ETS1 and FLI1 described in some post-transplant lympho-
proliferative disorders.30,31 On the other hand, although the
11q23 gain/11q24-qter loss of BLL-11q is mainly absent in
other lymphoma entities, its detection should not be con-
sidered as a unique feature to diagnose BLL-11q cases
since some transformed follicular lymphomas may carry a
similar 11q aberration pattern.22
In summary, BLL-11q is a GC-derived lymphoma with
genomic and mutational profiles closer to those of
HGBCL or GCB-DLBCL rather than BL in which the 11q
aberration, together with other mutations, may play a rel-
evant role in pathogenesis. These observations support a
reconsideration of the “Burkitt-like” term for these
tumors. Although, the most appropriate name is not easy
to propose and requires broader discussion and consensus,
we think that the term “aggressive B-cell lymphoma with
11q aberration” captures their pathological features. To
identify these cases we suggest performing copy number
arrays or FISH with the 11q probe in cases with BL,
DLBCL, and HGBCL morphology, a GC phenotype and
very high proliferative index (>90%), without MYC
rearrangements, in young patients. The recognition of
these tumors is clinically relevant because they have a
favorable outcome after therapy, although further studies
are needed to determine the optimal clinical management.
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